Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis
NCT04261023 · University of Leeds · PHASE2 · terminated · last registry update 2025-03-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The CI terminated ARCADIA early due to a number of reasons. These include the difficulty in recruiting and being placed on pause during the COVID pandemic, plus limited staffing at that time \& the need to considerably amend the eCRF MACRO system” | – | Registry record, University of Leeds |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-26Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Cyclosporine A (CsA) + Sirolimus (NCT07366801)
- 2026-01-23Results posted on the registry: Duke University, Abatacept Injection (NCT03841357)
- 2026-01-12Also stopped (withdrawn): University of Utah, Abatacept 10 mg/kg (NCT04344873)
- 2025-12-10Also stopped (terminated): University Hospital, Grenoble, Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab (NCT05145296)
- 2025-09-09Phase 3 first posted: Coya Therapeutics, COYA 302 + Placebo (NCT07161999)
- 2025-03-04Also stopped (terminated): Roswell Park Cancer Institute, Abatacept + Dexamethasone (NCT03457142)
- 2025-01-07Results posted on the registry: Rohit Aggarwal, MD, Abatacept (NCT03215927)
- 2025-01-01Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 (NCT06756152)
- 2024-10-23Phase 3 first posted: Duke University, TNFi (Tumor Necrosis Factor inhibitor) medication + Abatacept (NCT06654882)
- 2024-10-15Results posted on the registry: Bristol-Myers Squibb, Abatacept + Adalimumab (NCT04909801)
- 2024-10-09Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), lulizumab pegol + antithymocyte globulin (rabbit) (NCT04066114)
- 2024-10-02Results posted on the registry: Dimitrios Tzachanis, MD PhD, Cyclophosphamide + abatacept (NCT03680092)
- 2024-07-30Results posted on the registry: University of Washington, Abatacept (NCT03882008)
- 2024-06-26Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Baricitinib (NCT06475820)
- 2024-06-06Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), CTLA4-Ig (Abatacept) + Placebo (NCT01773707)
- 2024-05-16Results posted on the registry: Roswell Park Cancer Institute, Abatacept + Dexamethasone (NCT03457142)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision